Increased SARS-CoV-2 reactive low avidity T cells producing inflammatory cytokines in pediatric post-acute COVID-19 sequelae (PASC).
Paniskaki, Krystallenia, Goretzki, Sarah, Anft, Moritz et al. · Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2023 · DOI
Quick Summary
This study looked at children who had COVID-19 and developed long-lasting symptoms like breathing problems, fatigue, and brain fog—a condition called pediatric long COVID. Researchers found that these children had more immune cells fighting the virus that were less effective than usual, and these cells released inflammatory chemicals that may have been causing their symptoms. The findings suggest that ongoing immune system activation after COVID-19 might explain why some children develop persistent health problems similar to ME/CFS.
Why It Matters
This study provides mechanistic insights into how persistent immune activation following viral infection may contribute to ME/CFS-like symptoms in children, bridging post-COVID sequelae research with ME/CFS pathophysiology. Understanding these immune signatures could eventually inform targeted therapeutic approaches for both pediatric long COVID and ME/CFS patients who may share similar underlying mechanisms.
Observed Findings
Higher frequencies of spike-reactive CD4+ and CD8+ T cells in PASC children compared to convalescent controls
SARS-CoV-2-reactive T cells in PASC group produced TNFα and IFNγ and displayed low functional avidity
Positive correlation between CRP levels and IFNγ-producing reactive CD8+ T cells in PASC patients
Most common PASC symptoms included dyspnea/exercise intolerance, paresthesia, smell/taste disturbance, chest pain, headache, and concentration difficulties
Standard blood count and clinical chemistry showed no statistical differences between groups
Inferred Conclusions
Persistent cellular inflammatory response triggered by SARS-CoV-2 may be involved in the development of pediatric PASC symptoms
Low-avidity T cell responses with elevated inflammatory cytokine production distinguish PASC cases from asymptomatic convalescent children
These immunological mechanisms suggest potential targets for future therapeutic and prevention strategies in long COVID
Remaining Questions
Do these low-avidity T cell signatures persist over time, and how do they evolve during recovery or disease progression?
What determines whether some children develop PASC with these immune abnormalities while others recover normally?
What This Study Does Not Prove
This study does not prove that low-avidity T cells directly cause PASC symptoms—it shows correlation, not causation. The cross-sectional design captures only a single timepoint and cannot establish whether immune abnormalities precede symptom onset or result from ongoing symptoms. Results cannot be generalized beyond the small pediatric cohort studied.